H.C. Wainwright Downgrades Paratek Pharmaceuticals (PRTK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts PRTK Hot Sheet
Price: $2.23 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 14
Join SI Premium – FREE
H.C. Wainwright analyst Ed Arce downgraded Paratek Pharmaceuticals (NASDAQ: PRTK) from Buy to Neutral with a price target of $2.15.
For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.
Shares of Paratek Pharmaceuticals closed at $2.17 yesterday.
You May Also Be Interested In
- William Blair Downgrades Moderna (MRNA) to Market Perform
- Rosenblatt Downgrades OneSpan Inc. (OSPN) to Neutral
- Texas Capital Securities Downgrades Range Resources (RRC) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
